Heard K A, Russell T A
Nashville VAMC Dialysis Unit, USA.
Nephrol Nurs J. 2000 Dec;27(6):607-11.
Are occurrences of vascular access thrombosis and hospitalization higher in hemodialysis patients with hematocrits (Hcts) > 36% compared to those < 36%? This 12-month retrospective study included 30 male hemodialysis patients who received erythropoietin (rHuEPO) for at least 6 months. Sixty percent (n = 18) had arteriovenous fistulas and 40% (n = 12) had polytetrafluoroethylene grafts. The mean age was 59.6 years. Twenty patients during 216 patient months had a mean Hct < 36% with five thromboses (2.3%). Ten patients during 118 patient months had a mean Hct > 36% with four thromboses (3.4%). There was no statistically significant difference between the thrombosis rates in the two groups. There were four hospitalizations in 118 patient months in the > 36% group (3.4%). There were 33 hospitalizations in 216 patient months in the < 36% group (15.3%). This is 4.5 times higher than the > 36% group. Our data suggest that Hcts > 36% are not associated with increased thrombosis and are associated with lower hospitalization rates.
与血细胞比容（Hct）< 36%的血液透析患者相比，Hct > 36%的患者血管通路血栓形成和住院发生率是否更高？这项为期12个月的回顾性研究纳入了30名接受促红细胞生成素（rHuEPO）治疗至少6个月的男性血液透析患者。60%（n = 18）的患者有动静脉内瘘，40%（n = 12）的患者有聚四氟乙烯移植物。平均年龄为59.6岁。20名患者在216个患者月期间的平均Hct < 36%，发生了5次血栓形成（2.3%）。10名患者在118个患者月期间的平均Hct > 36%，发生了4次血栓形成（3.4%）。两组的血栓形成率之间无统计学显著差异。Hct > 36%组在118个患者月中有4次住院（3.4%）。Hct < 36%组在216个患者月中有33次住院（15.3%）。这比Hct > 36%组高4.5倍。我们的数据表明，Hct > 36%与血栓形成增加无关，且与较低的住院率相关。
